Evidence map›Paper›PMID 34499434›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats.

Caitlin L Maikawa, Peyton C Chen, Eric T Vuong, Leslee T Nguyen, Joseph L Mann, Andrea I d'Aquino, Rayhan A Lal, David M Maahs, Bruce A Buckingham, Eric A Appel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  5. Discrete, Chiral Polymer-Insulin Conjugates.Journal of the American Chemical Society · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Caitlin L MaikawaDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Peyton C ChenDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Eric T VuongDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Leslee T NguyenDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Joseph L MannDepartment of Materials Science & Engineering, Stanford University, Stanford, CA, 94305, USA.
Andrea I d'AquinoDepartment of Materials Science & Engineering, Stanford University, Stanford, CA, 94305, USA.
Rayhan A LalDepartment of Medicine (Endocrinology), Stanford University, Stanford, CA, 94305, USA.
David M MaahsDepartment of Pediatrics (Endocrinology), Stanford University, Stanford, CA, 94305, USA.
Bruce A BuckinghamDepartment of Pediatrics (Endocrinology), Stanford University, Stanford, CA, 94305, USA.
Eric A AppelDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0002-2301-7126
Stanford University · USStanford Medicine · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of DiabetesR01DK119254 · NIDDK · STANFORD UNIVERSITY · PI APPEL, ERIC ANDREW · 2019 to 2023
$2.9M
American Diabetes Association Grant 1-18-JDF-011NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK119254NIDDK R01 #R01DK119254PhRMA FoundationStanford Diabetes Research Center NIDDK #P30DK116074
6 · The paper itself

Abstract

Dual-hormone replacement therapy with insulin and amylin in patients with type 1 diabetes has the potential to improve glucose management. Unfortunately, currently available formulations require burdensome separate injections at mealtimes and have disparate pharmacokinetics that do not mimic endogenous co-secretion. Here, amphiphilic acrylamide copolymers are used to create a stable co-formulation of monomeric insulin and amylin analogues (lispro and pramlintide) with synchronous pharmacokinetics and ultra-rapid action. The co-formulation is stable for over 16 h under stressed aging conditions, whereas commercial insulin lispro (Humalog) aggregates in 8 h. The faster pharmacokinetics of monomeric insulin in this co-formulation result in increased insulin-pramlintide overlap of 75 ± 6% compared to only 47 ± 7% for separate injections. The co-formulation results in similar delay in gastric emptying compared to pramlintide delivered separately. In a glucose challenge, in rats, the co-formulation reduces deviation from baseline glucose compared to insulin only, or separate insulin and pramlintide administrations. Further, comparison of interspecies pharmacokinetics of monomeric pramlintide suggests that pharmacokinetics observed for the co-formulation will be well preserved in future translation to humans. Together these results suggest that the co-formulation has the potential to improve mealtime glucose management and reduce patient burden in the treatment of diabetes.

Indexed as

AcetaminophenAnimalsBlood GlucoseDiabetes Mellitus, ExperimentalDrug CompoundingGastric EmptyingGlucose Tolerance TestHalf-LifeHypoglycemic AgentsInfusions, SubcutaneousInsulinInsulin LisproIslet Amyloid PolypeptideMaleRatsRats, Sprague-DawleyAcetaminophenBlood GlucoseHypoglycemic AgentsInsulinInsulin LisproIslet Amyloid Polypeptidepramlintideamylindiabetesdrug deliveryhormonesinsulin

Identifiers

PMID34499434
PMCPMC8564421
OpenAlexW3197028991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.